Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.

Saved in:
Bibliographic Details
Title: Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.
Authors: Cremolini C; Unit of Medical Oncology 2, Department of Translational Research and New Technologies in Medicine and Surgery, Azienda Ospedaliera-Universitaria Pisana, University of Pisa, Pisa, Italy., Antoniotti C; Unit of Medical Oncology 2, Department of Translational Research and New Technologies in Medicine and Surgery, Azienda Ospedaliera-Universitaria Pisana, University of Pisa, Pisa, Italy., Lonardi S; Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto-IRCCS, Padova, Italy., Aprile G; Department of Oncology, University and General Hospital, Udine, Italy.; Department of Oncology, San Bortolo General Hospital, ULSS8 Berica, East District, Vicenza, Italy., Bergamo F; Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto-IRCCS, Padova, Italy., Masi G; Unit of Medical Oncology 2, Department of Translational Research and New Technologies in Medicine and Surgery, Azienda Ospedaliera-Universitaria Pisana, University of Pisa, Pisa, Italy., Grande R; Department of Medical Oncology, Hospital of Frosinone, Frosinone, Italy., Tonini G; Dipartimento di Oncologia Università Campus Bio-Medico di Roma, Rome, Italy., Mescoli C; Surgical Pathology and Cytopathology Unit, Department of Medicine, University of Padua, Padova, Italy., Cardellino GG; Department of Oncology, University and General Hospital, Udine, Italy., Coltelli L; Unit of Medical Oncology, Hospital Felice Lotti, Azienda Toscana Nord Ovest, Pontedera, Italy., Salvatore L; Unit of Medical Oncology 2, Department of Translational Research and New Technologies in Medicine and Surgery, Azienda Ospedaliera-Universitaria Pisana, University of Pisa, Pisa, Italy.; Unit of Medical Oncology, Policlinico G. B. Rossi, Azienda Ospedaliera Integrata di Verona, Verona, Italy., Corsi DC; Unit of Medical Oncology, Hospital San Giovanni Calibita Fatebenefratelli, Rome, Italy., Lupi C; Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy., Gemma D; Department of Medical Oncology, Hospital of Frosinone, Frosinone, Italy., Ronzoni M; Department of Oncology, Hospital San Raffaele IRCSS, Milan, Italy., Dell'Aquila E; Dipartimento di Oncologia Università Campus Bio-Medico di Roma, Rome, Italy., Marmorino F; Unit of Medical Oncology 2, Department of Translational Research and New Technologies in Medicine and Surgery, Azienda Ospedaliera-Universitaria Pisana, University of Pisa, Pisa, Italy., Di Fabio F; Unit of Medical Oncology, Policlinico Sant'Orsola-Malpighi, Bologna, Italy., Mancini ML; Department of Medical Oncology, Policlinico Umberto I Sapienza, University of Rome, Rome, Italy., Marcucci L; Unit of Medical Oncology, Hospital Felice Lotti, Azienda Toscana Nord Ovest, Pontedera, Italy., Fontanini G; Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy., Zagonel V; Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto-IRCCS, Padova, Italy., Boni L; Clinical Trials Coordinating Center, Toscano Cancer Institute, University Hospital Careggi, Florence, Italy., Falcone A; Unit of Medical Oncology 2, Department of Translational Research and New Technologies in Medicine and Surgery, Azienda Ospedaliera-Universitaria Pisana, University of Pisa, Pisa, Italy.
Source: JAMA oncology [JAMA Oncol] 2018 Apr 01; Vol. 4 (4), pp. 529-536.
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2374-2445
DOI:10.1001/jamaoncol.2017.5314